Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Lymphoma

Free Subscription 29.04.2024 1 Am J Hematol 4 Blood 1 Br J Haematol 1 Cancer Res 1 Curr Treat Options Oncol 3 Eur J Haematol 1 Haematologica 2 Lab Invest 4 Leuk Lymphoma 1 Mod Pathol 1 N Engl J Med 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. MA S, La J, Swinnerton KN, Guffey D, et al
   Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study.
   Am J Hematol. 2024 Apr 23. doi: 10.1002/ajh.27335.
   PubMed         Abstract available
   
   

   
   Blood

2. SARKOZY C, Callanan MB, Thieblemont C, Oberic L, et al
   Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
   Blood. 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944.
   PubMed         Abstract available
   
   
3. HANDUNNETTI SM, Anderson MA, Burbury KI, Thompson PA, et al
   Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
   Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388.
   PubMed         Abstract available
   
   
4. CROCHET G, Iacoboni G, Couturier A, Bachy E, et al
   Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
   Blood. 2024 Apr 24:blood.2024024526. doi: 10.1182/blood.2024024526.
   PubMed         Abstract available
   
   
5. MAYBURY BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, et al
   Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.
   Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048.
   PubMed         Abstract available
   
   

   
   Br J Haematol

6. HUO W, Gao L, Song K, Huang J, et al
   Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
   Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
   PubMed         Abstract available
   
   

   
   Cancer Res

7. ITO Y, Marouf A, Kogure Y, Koya J, et al
   Comprehensive genetic profiling reveals frequent alterations of driver genes on the X chromosome in extranodal NK/T-cell lymphoma.
   Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-24-0132.
   PubMed         Abstract available
   
   

   
   Curr Treat Options Oncol

8. CHERNG HJ, Herrera A
   Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
   Curr Treat Options Oncol. 2024 Apr 24. doi: 10.1007/s11864-024-01201.
   PubMed         Abstract available
   
   

   
   Eur J Haematol

9. KUTSCH N, Godel P, Voltin CA, Hallek M, et al
   Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
   Eur J Haematol. 2024;112:984-987.
   PubMed         Abstract available
   
   
10. HARMANEN M, Sorigue M, Khan M, Prusila R, et al
    Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis.
    Eur J Haematol. 2024 Apr 25. doi: 10.1111/ejh.14219.
    PubMed         Abstract available
    
    
11. PERNAS B, Iacoboni G, Los-Arcos I, Carpio C, et al
    Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis.
    Eur J Haematol. 2024 Apr 26. doi: 10.1111/ejh.14207.
    PubMed         Abstract available
    
    

    
    Haematologica

12. LINK BK
    Follicular lymphoma treatment decisions: put GELF on the shelf?
    Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285286.
    PubMed         Abstract available
    
    

    
    Lab Invest

13. WANG XG, Yin WH, Wang HY
    Indolent T-Cell/Natural Killer-Cell Lymphomas/Lymphoproliferative Disorders of the Gastrointestinal Tract-What Have We Learned in the Last Decade?
    Lab Invest. 2024;104:102028.
    PubMed         Abstract available
    
    
14. KAWADE G, Kurata M, Matsuki Y, Fukuda S, et al
    Mediation of Ferroptosis Suppressor Protein 1 Expression via 4-Hydroxy-2-Nonenal Accumulation Contributes to Acquisition of Resistance to Apoptosis and Ferroptosis in Diffuse Large B-Cell Lymphoma.
    Lab Invest. 2024;104:102027.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

15. VON ROEMELING C, Ferreri AJM, Soussain C, Tun HW, et al
    Targets and treatments in primary CNS lymphoma.
    Leuk Lymphoma. 2024 Apr 24:1-13. doi: 10.1080/10428194.2024.2342560.
    PubMed         Abstract available
    
    
16. MCNALLY GA, Aossey CM, Wiczer T, Sinnott LT, et al
    A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH +/- R: does HIV status matter?
    Leuk Lymphoma. 2024 Apr 22:1-7. doi: 10.1080/10428194.2024.2340051.
    PubMed         Abstract available
    
    
17. TABARI E, Lovejoy AF, Lin H, Bolen CR, et al
    NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.
    Leuk Lymphoma. 2024;65:618-628.
    PubMed         Abstract available
    
    
18. TUCCI A, Masina L, Luminari S
    Curative intent therapy for DLBCL in the elderly.
    Leuk Lymphoma. 2024;65:560-569.
    PubMed         Abstract available
    
    

    
    Mod Pathol

19. MEDEIROS LJ, Chadburn A, Natkunam Y, Naresh KN, et al
    Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms.
    Mod Pathol. 2024;37:100441.
    PubMed         Abstract available
    
    

    
    N Engl J Med

20. HU Y, Zhang M, Yang T, Mo Z, et al
    Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
    N Engl J Med. 2024;390:1467-1480.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

21. LI MY, Chong LC, Duns G, Lytle A, et al
    TRAF3 loss-of-function reveals the noncanonical NF-kappaB pathway as a therapeutic target in diffuse large B cell lymphoma.
    Proc Natl Acad Sci U S A. 2024;121:e2320421121.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.